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Abstract
Background: The angiotensin-converting enzyme (ACE) inhibitors have complicated and poorly
characterized pharmacokinetics. There are two binding sites per ACE (high affinity "C", lower
affinity "N") that have sub-nanomolar affinities and dissociation rates of hours. Most inhibitors are
given orally in a prodrug form that is systemically converted to the active form. This paper
describes the first human physiologically based pharmacokinetic (PBPK) model of this drug class.
Methods: The model was applied to the experimental data of van Griensven et. al for the
pharmacokinetics of ramiprilat and its prodrug ramipril. It describes the time course of the
inhibition of the N and C ACE sites in plasma and the different tissues. The model includes: 1) two
independent ACE binding sites; 2) non-equilibrium time dependent binding; 3) liver and kidney
ramipril intracellular uptake, conversion to ramiprilat and extrusion from the cell; 4) intestinal
ramipril absorption. The experimental in vitro ramiprilat/ACE binding kinetics at 4°C and 300 mM
NaCl were assumed for most of the PBPK calculations. The model was incorporated into the freely
distributed PBPK program PKQuest.
Results: The PBPK model provides an accurate description of the individual variation of the plasma
ramipril and ramiprilat and the ramiprilat renal clearance following IV ramiprilat and IV and oral
ramipril. Summary of model features: Less than 2% of total body ACE is in plasma; 35% of the oral
dose is absorbed; 75% of the ramipril metabolism is hepatic and 25% of this is converted to systemic
ramiprilat; 100% of renal ramipril metabolism is converted to systemic ramiprilat. The inhibition
was long lasting, with 80% of the C site and 33% of the N site inhibited 24 hours following a 2.5 mg
oral ramipril dose. The plasma ACE inhibition determined by the standard assay is significantly less
than the true in vivo inhibition because of assay dilution.
Conclusion: If the in vitro plasma binding kinetics of the ACE inhibitor for the two binding sites
are known, a unique PBPK model description of the Griensven et. al. experimental data can be
obtained.
Published: 06 January 2006
BMC Clinical Pharmacology 2006, 6:1 doi:10.1186/1472-6904-6-1
Received: 06 September 2005
Accepted: 06 January 2006
This article is available from: http://www.biomedcentral.com/1472-6904/6/1
© 2006 Levitt and Schoemaker; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
Page 2 of 27
(page number not for citation purposes)
Background
The angiotensin-converting enzyme (ACE) inhibitors are
one of the worst characterized drug classes in terms of
their quantitative pharmacokinetics and pharmacody-
namics. There are a number of factors that complicate the
analysis of this drug class:
1) The ACE enzyme in plasma and tissue has a very high
affinity (sub nanomolar) for the ACE inhibitors. This pro-
duces extremely non-linear kinetics as the concentration
falls from high concentrations when most of the drug is
free, to low concentrations when most of the drug is
bound to ACE.
2) Although it is known that more than 90% of the total
ACE is in the tissues, the quantitative distribution of tissue
ACE is not well characterized.
3) Although it is known that ACE has two sites with differ-
ent inhibitor binding constants, the physiological values
of these binding constants are not known.
4) The two ACE binding sites have different catalytic sub-
strate selectivity. Predicting the pharmacodynamics of the
ACE inhibitors requires knowledge of these substrate
activities.
5) The rate of dissociation of the inhibitor from ACE is so
slow (hours) that one cannot assume that there is instan-
taneous equilibrium between the free and bound inhibi-
tor.
6) Assays of the ACE inhibition are unreliable because of
uncertainties about the relationship between the in vivo
inhibition and the inhibition measured in the standard
ACE assay.
7) Most ACE inhibitors are administered orally in the
form of a prodrug that is systemically converted to the
active inhibitor. Prediction of the pharmacokinetics of the
active form requires an understanding of the pharmacok-
inetics of the prodrug and drug and the details of the con-
version of the prodrug to the active form in the liver and
kidney.
This paper presents the first attempt to describe a quanti-
tative human physiologically based pharmacokinetic
model (PBPK) of the ACE inhibitors. The model describes
the pharmacokinetics in terms of realistic human param-
eters such as the organ blood flows, tissue cellular and
extracellular volume and cell membrane permeability.
The model incorporates all of the complexities listed
above. It is implemented in PKQuest, a general pharma-
cokinetic software routine that has now been applied to
more than 25 different solutes with a wide range of phar-
macokinetic properties [1-8]. Many of the physiological
parameters of the model have been determined previously
by application of PKQuest to other drugs and are used
directly without modification in this ACE inhibitor
model. This includes the tissue blood flows, extracellular
volume of distribution of the different tissues, and the tis-
sue albumin concentration (which is important because
of non-specific ACE inhibitor albumin binding).
Although it is now generally recognized that rational drug
therapy should be based on the quantitative degree on tis-
sue ACE inhibition [9], the dependence of the pharmaco-
dynamic effect on plasma drug levels and ACE activity is
still not clear [10-12]. Huge efforts have been directed at
determining optimum dosage with limited results [13]. It
will be shown that this PBPK model has the potential to
provide direct quantitative information about the time
and dose dependence of the ACE inhibition in the differ-
ent tissues.
It has been known for many years that inhibitor binding
to ACE was of the "slow tight" class, with dissociation
constants in the sub-nanomolar range, and time constants
for release from the tight complex of many hours. Because
of the non-linear binding curves, it was initially assumed
that the binding of the inhibitor (R) to the free enzyme
(E) was a two step process:
with rapid formation of a loose complex (REL) followed
by a slow conversion to the tight form (RET) [14-18].
When it was recognized that ACE had two homologous
extracellular binding sites (referred to as the "N" and "C"
terminal sites), it became apparent that the non-linearity
resulted from the presence of these two sites and that the
kinetics of each site could be described as a one step proc-
ess characterized by two equilibrium dissociation con-
stants KN and KC (nM) and unbinding rate constants k-N
and k-C (1/min) [19]:
There is conflicting data about the interaction between the
two sites (see [20] for recent discussion). In the most
detailed experimental measurements of the ACE binding
kinetics, Wei et. al. [19] found that the two sites acted
independently in the binding of [3H]trandolaprilat. It is
assumed here that the N and C site binding of ramiprilat
is also independent.
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The only quantitative kinetic measurements of Ki and k-i
for ramiprilat binding to the two sites is at 4°C and 300
mM NaCl [21]. Measurements of the rate of substrate
hydrolysis indicates that, in going from 25°C and 300
mM Cl- to 37°C and 120 mM Cl-, the change in apparent
Ki of ramiprilat is small because the temperature and chlo-
ride change tend to cancel each other [22]. In the follow-
ing analysis, as a first approximation, it will be assumed
that the physiological (37°C and 100 mM Cl) binding
constants for the two sites (eq. (2)) are equal to the exper-
imental values at 4°C and 300 mM NaCl.
Although there have been some reports of different bind-
ing properties of plasma and tissue ACE [23-27], the dif-
ferences are small and could be an artifact of the difficulty
of assaying these very high affinity ("tight") enzymes (see
below). Since it has been established that the circulating
ACE in the plasma is derived from the membrane bound
tissue ACE by post-translational proteolytic cleavage
[28,29], it will be assumed, as a first approximation, that
the circulating and tissue ACE are identical. (A major
exception is testis ACE which contains only the C terminal
domain binding site [21].) This is an important consider-
ation because it allows one to use measurements of the
fraction of the circulating plasma ACE that is occupied by
bound inhibitor to determine the ACE inhibition in the
different tissues – the clinically important factor.
Previous attempts to model the pharmacokinetics and
pharmacodynamics of the ACE inhibitors have used com-
partmental models and were not physiologically based
(i.e., using known organ blood flows, etc.) [30-34].
Toutain and colleagues have developed detailed compart-
ment models and used them to accurately describe the
non-linear pharmacokinetics/pharmacodynamics of a
number of high affinity ACE inhibitors in animals [30-
32]. The most important previous modeling of ramiprilat
in humans is that of Brockmeier [35,36] who recognized
that the renal clearance of ramiprilat provided a direct
measurement of the fraction that was free in plasma and
used this measurement to estimate the physiological ram-
iprilat ACE binding constant. All of these earlier models
have been limited by the assumption of a single ACE
binding site and equilibrium binding and they have not
attempted to model the processes involved in the conver-
sion of the prodrug to the drug.
The PBPK model that is applied here to the ACE inhibitors
is summarized in fig. 1. It has two features that are imple-
mented for the first time in a PBPK model. The first is the
use of a time dependent binding (eq. (2)) in each of the
tissues, in place of the usual assumption of equilibrium
binding. The second is the physiological model of the cel-
lular uptake and intracellular conversion of ramipril to
ramiprilat and the subsequent extrusion to the circulating
blood. These features have been implemented in the
freely distributed software program PKQuest [37].
The model is applied to the detailed pharmacokinetic
analysis of ramipril (prodrug) and ramiprilat (the active
dicarboxylic acid ACE inhibitor) previously described by
van Griensven et. al[38]. This is an open, randomized,
three-way cross-over study that measured: 1) the plasma
ramiprilat following an intravenous (IV) ramiprilat infu-
sion; 2) plasma ramipril and ramiprilat following an IV
ramipril infusion; and 3) plasma ramipril and ramiprilat
after oral ramipril. In addition, plasma ACE activity and
the urinary excretion of ramipril, ramiprilat and the major
metabolites were measured in all 3 arms. The requirement
that a single PBPK model must be able to describe all these
data sets places strong constraints on the model and
severely limits the range of the allowed model parameters.
Methods
Notation
R, D – free, unbound, concentration of ramipril and ram-
iprilat, respectively.
PBPK model of the pharmacokinetics of prodrug ramipril (R)  and active drug ramiprilat (D) Figure 1
PBPK model of the pharmacokinetics of prodrug ramipril (R) 
and active drug ramiprilat (D). The figure schematically illus-
trates the events in three different tissues (typical "tissue", 
the liver and the kidney), the intestinal absorption, the renal 
clearance and enterohepatic recirculation.
D, D’ = free extracellular and intracellular prodrug (ramipril) concentration.
R, R’ = free extracellular and intracellular active drug (ramiprilat) concentration 
E = free ACE concentration        A = albumin
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kN, kC, k-N, k-C – association (1/(nM min)) and dissocia-
tion rate (1/min) rate constants for N terminal and C ter-
minal ACE binding site.
KN, KC – equilibrium disassociation constant for N termi-
nal and C terminal ACE binding site.
Cl – plasma clearance in terms of total plasma concentra-
tion.
Clu, ClR – free (unbound) and total arterial kidney rami-
prilat clearance.
Clint_L, Clint_K – intrinsic liver and kidney clearance of ram-
ipril in terms of free, unbound tissue concentration.
fu, fu_cell – fraction unbound in plasma and in intracellular
water.
Vw – intracellular water volume.
P, S, Ps – Cell membrane permeability, surface area, and
permeability coefficient (Ps = PS/Vw)
AD, a, T – gamma function parameters describing intesti-
nal absorption of ramipril (AD = total amount absorbed.).
AR, Aslow – amount of intestinal absorption in the form of
ramiprilat and the slow ramipril absorption component.
The PBPK model
This section describes the main features of the model. See
additional file ACE_supplemental_31oct05.doc (section
I) for a detailed mathematical description. The arrange-
ment of the different tissues is shown in fig. 2. The tissue
parameters (blood flow, volumes, etc.) are listed in Table
1 and are identical to those used in previous applications
of PKQuest [1-8]. The connective tissue is divided
between two organs: "tendon" with a relatively low blood
flow, and "other" with a higher blood flow. The "stand-
ard" organ blood flows are assumed and the small
changes in peripheral blood flow produced by ramipril
[39] are neglected. ACE inhibitors do not produce a signif-
icant change in cardiac output [40].
Figure 1 shows a more detailed view of the model that
focuses on 3 tissues: the liver, kidney, and one represent-
ative "tissue" region. "D" is the free prodrug (ramipril)
concentration, and "R" is the free active drug (ramiprilat)
concentration. The top square, labeled "tissue" shows the
kinetic processes in a typical tissue region. Both the highly
water soluble ramiprilat (R) and the tissue ACE binding
sites are restricted to the extracellular space (EC). (Excep-
tions are the liver and kidney which have ramiprilat cell
membrane transport systems.) The fraction of tissue vol-
ume that is extracellular has been determined previously
[6]. As described in eq. 2, it is assumed that ACE has two
non-interacting binding sites (labeled as "C" and "N" ter-
minal) with different ramiprilat binding constants
[19,21] (only one binding site is shown in fig. 1). The
binding for each site is characterized by the two parame-
ters: k-i the unbinding rate constant; and Ki the dissocia-
tion equilibrium constant (ki = k-i/Ki). The amount bound
is described quantitatively by the differential equations:
There is also a non-specific, non-saturating equilibrium
ACE inhibitor binding to the plasma and tissue albumin
(A) characterized by the albumin binding constant (BR):
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Schematic diagram of the arrangement of the different tissues  in the PBPK model Figure 2
Schematic diagram of the arrangement of the different tissues 
in the PBPK model. The organ "portal" refers to all the 
organs drained by the portal vein. The connective tissue is 
divided between two organs: "tendon" with a relatively low 
blood flow and "other" with a higher blood flow.
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As describe in the additional file 1
ACE_supplemental_31oct05.doc (section I), the amount
of albumin binding in the different tissues can be deter-
mined from the experimental value for the fraction of
albumin bound ramiprilat in plasma (= 0.56 [41]) and
the previously determined "standard human" PKQuest
values for the tissue extracellular albumin [6]. This sup-
plemental file section also describes in more detail how
the above relations for ramiprilat are incorporated into
the PKQuest PBPK routine.
The PBPK analysis indicates that ramipril has a finite cell
membrane permeability that allows it to enter the intrac-
ellular space (IC) (see fig. 1, "tissue"). This is consistent
with the relatively high octanol/water partition coefficient
at pH 7 of 1.12 of ramipril, one hundred fold greater than
that of ramiprilat (0.011) [42]. The rate of exchange
between the intracellular and extracellular space is deter-
mined by two parameters: 1) the cell membrane permea-
bility coefficient (Ps); and 2) the fraction of intracellular
solute that is unbound (fu_cell):
where D and D' are the free extracellular and intracellular
ramipril concentration and Ps is the cellular permeability
coefficient (P = permeability, S = surface area, and Vw =
intracellular water volume). Extracellular ramipril is also
bound to albumin, similar to the binding of ramiprilat
(eq. (4)).
The ramiprilat and ramipril kinetics discussed above and
illustrated in fig. 1 for the box labeled "tissue" is present
in all the tissues, including the liver and kidney and cen-
tral venous and arterial compartment (binding not shown
in fig. 1). Each tissue i is characterized by 3 parameters: 1)
total ACE concentration (ACEi) with two sites per each
ACE molecule (EtC
i = EtN
i = ACEi); 2) ramipril cell mem-
brane permeability coefficient (Psi) and 3) intracellular
ramipril binding (fu_cell). In addition, the ramiprilat liver
and kidney Ps and fu_cell must be defined. The ramiprilat
ACE binding constants (KN, KC, k-N, k-C) are assumed to be
identical for all tissues.
Both the liver and kidney metabolize the intracellular
ramipril (D'). As shown in fig. 1, the liver metabolizes
ramipril to ramiprilat (R') and to a number of other
metabolites (indicated by M). Three parameters character-
ize this metabolism: the intrinsic liver (Clint_L) and kidney
(Clint_K) clearance and the fraction of total liver ramipril
metabolism that is converted to ramiprilat (FrL). (1- FrL is
converted to other metabolites). It is assume that all the
ramipril metabolized by the kidney is converted to rami-
prilat. The rate that the liver converts intracellular ramipril
(free concentration = D') to intracellular ramiprilat (R') is:
QR = Clint_LFrL D'   (6)
All the intracellular ramiprilat generated by the liver and
kidney eventually enters the systemic circulation (see eq.
(5)). The intrinsic clearance is in terms of the free concen-
tration. For a flow limited, well stirred tissue, the absolute
clearance (Cl) can be approximately related to the intrin-
sic clearance (Clint) in terms of the organ flow (F), and
fraction unbound (fu):
Cl = fu Clint F/(F + fu Clint)   (7)
As illustrated in fig. 1, the extracellular ramiprilat is not
metabolized or excreted by the liver. The only excretory
dD
dt
fP s D D P s P S V uc e l l w
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Table 1: Standard human population PBPK organ parameters (not varied).
Organ Weight 
(Kg)
ECF 
water(L)
Flow (L/
min)
ACE Tiss/
Plasma
Ramiprialat 
Ps (min-1)
Ramiprilat 
fu_cell
Ramipril Ps 
(min-1)
Ramipril 
fu_cell
Blood 5.5 2.68345 0.52 0 ----
liver 1.8 0.2898 0.45 1.37 Adjustable 1 infinite 0.1
portal  1.5 0.351 1.125 2.0 0 ---- 0.05 0.5
muscle 26 3.042 0.585 1.0 0 ---- 0.05 0.5
kidney 0.31 0.04092 1.24 5.62 Adjustable 10 infinite 0.01
brain 1.4 0 0.784 0.8 0 ---- 0.05 0.5
heart 0.33 0.066 0.264 1.7 0 ---- 0.05 0.5
lung 0.536 0.08576 5.6184 34 0 ---- 0.05 0.5
skin 2.6 1.092 0.26 3.51 0 ---- 0.05 0.5
tendon 3 2.55 0.03 7.23 0 ---- 0.05 0.5
other 5.524 3.75632 0.1104 5.79 0 ---- 0.05 0.5
bone 40000 - - - - 0 0 . 5
adipose 17.5 3.5 0.7385 6.81 0 ---- 0.05 0.5
Total 70 17.4572 5.5877BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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pathway removing ramiprilat is the renal excretion (Qkid-
ney) which is assumed to be proportional to the free,
unbound, arterial ramiprilat concentration (Rart):
Qkidney = Clu Rart   (8)
Where Clu is the unbound renal clearance. The unbound
concentration is related to the total arterial plasma con-
centration (RT_art) by the fraction unbound in arterial
plasma (fu):
Qkidney = Clu Rart = Clu fuRT_art = ClRRT_art   ClR = fuClu   (9)
where ClR is the renal total plasma clearance. Because of
the highly non-linear ramiprilat binding that results from
saturation of the ACE binding sites, the total renal clear-
ance (ClR) is non-linear: at high concentrations when
most of the ramiprilat is free (fu→ 1), the clearance is
equal to the intrinsic unbound clearance (ClR ≈ Clu ≈ 0.4
l/min), while at long times and low concentrations, when
most of the ramiprilat is bound, the clearance falls to val-
ues less than 0.02 l/min [35,36].
The observed delay in the systemic appearance of ramipri-
lat after either an oral or IV ramipril input depends on the
processes involved in the liver and kidney ramipril cellu-
lar uptake, intracellular conversion to ramiprilat and then
transport to the plasma. These processes have been
directly identified in an extensive series of investigations
of Pang and colleagues on the behavior of enalapril and
enalaprilat in perfused rat liver, kidney and intestine [43-
49].
Although there was an initial report that the intestinal
absorption was carrier mediated [50], Morrison et. al. [51]
have clearly shown that the absorption of enalapril is pri-
marily a non-saturable, passive diffusion process. There
are three different components for absorption of oral ram-
ipril (fig. 1). The major component is direct absorption of
ramipril into the portal circulation where it is subject to
first pass metabolism. This component is described by the
3 parameter gamma distribution (AD, T, a):
I(t) = ADbata-1 exp(-bt)/Γ(a)   b = a/T   (10)
where AD is the total amount absorbed, Γ is the gamma
function, a is the dimensionless gamma number and T is
a time constant. For most drugs this 3 parameter function
provides a good description of the time delay in oral
absorption produced by gastric emptying [5]. The three
parameters AD, a and T are adjusted for each subject. Pang
et. al. [48] have shown in the rat that there is a second
component in which some of the oral ramipril can be
directly converted to ramiprilat either in the lumen or the
intestinal epithelial cells and absorbed into the portal
blood. This second component produces a more rapid
systemic appearance of ramiprilat than the first compo-
nent because it bypasses the slower processes involved in
the liver and renal production of ramiprilat from ramipril.
It is assumed that this ramiprilat absorption has the same
Table 4: Intestinal absorption parameters for oral ramipril: 1) the major ramipril absorption component (gamma function, A, a, and 
T); 2) a slow, long ramipril component (Aslow); and 3) direct intestinal conversion and absorption of ramiprilat (gamma function, AR, a 
and T). The total oral dose is 2.5 mg (6010 nanomoles). The total amount absorbed = A + Aslow+ AR.
Subject Ramipril- Major component Slow absorp. 
Amount Aslow 
(nmole)
Ramprilat Amount 
AR (nmole)
Total Absorption 
(nmole)
Amount (A) 
(nmole)
Time const. (T) 
(min)
Gamma (a)
1 2500 90 3 787 200 3487
3 1200 53 9 367 60 1627
4 1600 45 8 432 30 2062
5 1400 48 3.2 0 100 1500
6 1800 35 3 0 100 1900
7 800 25 3 320 41 1161
8 2100 70 2 756 200 3056
9 2200 65 6 0 100 2300
10 1800 60 5.5 0 100 1900
11 1100 35 3 346 100 1546
12 2700 80 4 0 400 3100
Ave (SD) 1745 (597) 55.1 (20.1) 4.4 (2.3) 273 (301) 130 (105) 2149 (755)BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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time course as the major ramipril component (eq. (10))
with the same values of a and T and a value of A (= AR)
about 10% that of AD. Finally, in some subjects it was nec-
essary to add a second, much slower rate of ramipril
absorption that was described by a constant rate that
extended from 200 to 3000 minutes:
where Aslow is the total amount absorbed by this compo-
nent. In summary, the oral absorption is characterized by
5 parameters: AD, AR, Aslow, a and T (see Table 4).
All of these features were incorporated into PKQuest and
can be activated using a simple interactive menu. The
parameters describing the individual PBPK models of
each of the two solutes (ramipril and ramiprilat) are
entered first. The two solutes are then coupled by defining
the parameters Vmax [i,j,m] and Km [i,j,m] which are the
Michaelis-Menten parameters for metabolism of substrate
i to product j in tissue m. It is assumed that the ramipril
metabolism is liner, so that Km is set to a very large value
and Vmax is set equal to KmClint. An arbitrary number of
substrates and products are allowed. Most of the figures
used in this paper represent standard PKQuest output.
Model parameters
The PBPK model is characterized by a large number of
parameters. Most of these parameters are fixed and are
identical for all subjects (see Table 1). In addition there
are 12 parameters that are adjusted (see below) to fit the
data for each subject: 4 characterizing the ramiprilat phar-
macokinetics (Table 2); 3 characterizing the ramipril
metabolism (Table 3); and 5 characterizing the ramipril
intestinal absorption (Table 4). A brief description of
these parameters is listed here:
Ramiprilat ACE binding kinetics
The values determined by Deddish et. al. [21] at 4°C and
300 mM NaCl were used as the default "standard" values
for all subjects (see eq. (2)): N site (low affinity): KN = .276
nM; k-N = 0.0234/min; C site (high affinity): KC = 0.039
nM; k-C = 0.00168/min.
Plasma and tissue ACE concentration
The ACE concentration in normal human plasma deter-
mined using a radioimmunoassay varies from 220 to 730
ng/ml [29,52]. (A single genetic polymorphism accounts
for 50% of this normal variation). This corresponds to
1.29 to 4.29 nM, assuming a molecular weight of circulat-
ing ACE of 170 kDa [53]. The plasma ACE (ACEplasma) in
the PBPK model is a variable parameter, adjusted to opti-
mize the fit to the experimental data. The model values
varied from 1.13 to 2.9 nM for the different subject (Table
2). This is the lower end of the experimental range for
humans. The tissue ACE is defined by a standard tissue/
plasma ratio (listed in Table 1) and is identical for all sub-
jects. The lung, liver, heart, brain and GI tract ratios are in
rough agreement with experimental measurements in rats
or rabbits [23,54-56]. The skeletal muscle values are based
on needle biopsy measurements in humans [57,58].
Although there are high ACE concentrations in the kid-
ney, most of this activity is in the lumen of the proximal
tubule [59], a region that will have limited and slow con-
tact with the circulating ACE inhibitor [56]. The total tis-
sue ACE is 68 times the blood ACE. An essential
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Table 2: Ramiprilat Adjustable PBPK Parameters: Intrinsic renal clearance, ACE plasma concentration, and liver and kidney cell 
membrane permeability coefficient. The "average weighted residual error" of the PBPK model for the IV ramiprilat input is listed in 
the last column.
Subject Renal Clear. Clu (l/
min)
ACEplasma (nM) Membrane Permeability (Ps min-1) IV Ramiprilat Ave. 
Error
Liver Kidney
1 0.55 1.5 0.015 0.0003 0.11
3 0.4 2.35 0.007 0.0015 0.10
4 0.4 1.65 0.018 0.001 0.17
5 0.55 1.13 0.01 0.0006 0.16
6 0.4 1.25 0.015 0.002 0.27
7 0.7 2.25 0.01 0.0006 0.18
8 0.4 2.9 0.01 0.0006 0.11
9 0.37 1.75 0.008 0.0003 0.32
10 0.45 1.45 0.015 0.002 0.13
11 0.45 1.4 0.01 0.0003 0.30
12 0.4 2.25 0.006 0.0003 0.14
Ave (SD) 0.46 (0.10) 1.81 (0.55) 0.011 (0.0039) 0.00086 (0.00067) 0.18 (0.08)BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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qualitative feature of the PBPK modeling is the require-
ment for this large total ACE tissue/blood ratio (see
Results). High ACE concentrations have been assigned to
the loose connective tissue organs ("tendon" and "other")
and to "adipose" tissue based on the observation of Sun
et. al. [60] that there was high ACE concentration in sub-
cutaneous connective tissue. Especially important is the
high adipose tissue/plasma value of 6.8 because adipose
tissue makes a large contribution to the pharmacokinetics
because of it large weight (Table 1). Although there is no
quantitative adipose date in humans, it has been shown
that ACE mRNA is expressed in human adipose tissue
[61]. In rats, the subcutaneous fat/plasma ramiprilat bind-
ing ratio at 24 hours after an oral dose was about 5 [41].
Ramiprilat renal clearance
The intrinsic renal clearance (Clu, eq. (9)) was adjusted to
fit the data for each subject (Table 2).
Ramiprilat liver and kidney cell membrane permeability and 
intracellular binding
The product of the two parameters fu_cell and Ps deter-
mines the rate that the intracellular ramiprilat formed
from ramipril enters the systemic circulation (eq. (5)).
The value of fu_cell for the kidney and liver were assigned
arbitrary large values, corresponding to a low binding
(Table 1) and the values of Ps were adjusted for each sub-
ject (Table 2) to fit the experimental data.
Ramipril liver cell membrane permeability and intracellular binding
The ramipril Ps is finite for all tissues, allowing ramipril to
distribute in all the body water. The value of fu_cell deter-
mines the equilibrium volume of distribution and Ps
determines the time course of this equilibrium. The fixed
values listed in Table 1 were assigned to provide optimal
fits to the IV ramipril input.
Ramipril metabolic parameters
The intrinsic liver (Clint_L) and kidney (Clint_K) clearance
and the fraction of the liver clearance that is converted to
ramiprilat (FrL) were adjusted for each subject to fit the
oral and IV ramipril data (Table 3).
Ramipril intestinal absorption parameters
The values of the 5 parameters describing the intestinal
ramipril absorption (AD, a, T, AR, Aslow, eqs. (10) and
(11)) were adjusted to fit the individual subject data
(Table 4).
ACE assay
It is well recognized that the standard ACE plasma assay
in the presence of inhibitors may give a result that differs
significantly from the in vivo plasma activity [35,62,63].
The problem arises from the dilution and time dependent
effects that become important for the very tight and slow
ACE binding. In order to compare the experimental
plasma assay measurements with the PBPK model predic-
tions of the fraction of plasma ACE that is complexed with
inhibitor, it is necessary to develop a detailed kinetic
model of the assay procedure. The following analysis is
similar to that of Weisser and Schloos [63], except that
they assumed rapid, equilibrium binding, while this anal-
ysis use the more general time dependent binding model
(eq. (3)).
The ACE assay of the ramipril study used the Vertex kit
ACE assay [17] in which a 10 fold dilution of plasma is
incubated with 8 mM of the substrate p- [3H]benzoylgly-
Table 3: Ramipril adjustable PBPK parameters: 1) intrinsic liver clearance (Clint_L); 2) intrinsic kidney clearance (Clint_K; 3) the fraction 
of the liver ramipril clearance that is converted to systemic ramiprilat. The "average weighted residual error'' of the PBPK model 
plasma ramiprilat following either IV or oral ramipril is listed in the last two columns.
Subject Clint_L (l/min) Clint_K (l/min) Fraction to ramiprilat IV Ramipril Ave. Error Oral Ramipril Ave. 
Error
1 4.8 1.2 0.1 0.2 0.23
3 1 1.5 0.32 0.17 0.25
4 3.6 0.9 0.4 0.23 0.27
522 0 . 0 0 . 1 7 P o o r  f i t
6 3 1 0.25 0.23 0.28
7 4 1 0.2 0.14 0.14
85 . 500 . 4 0 . 1 3 0 . 2 2
9 3.48 0.52 0.2 0.12 0.38
10 3.5 1.5 0.4 0.30 0.34
11 2.8 1.2 0.3 0.23 0.14
12 6.16 0.84 0.2 0.13 0.2
Ave (SD) 3.62 (1.5) 1.06 (0.53) 0.25 (0.13) 0.19 (0.057) 0.24 (0.077)BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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cylglycylglycine for 60 minutes at 37°C in 100 mM NaCl.
Using the same notation as in eq. (2):
where EC, EN and Eti are the free C and N site and total
enzyme concentration, S is the free concentration of assay
substrate and I, IEC and IEN are the free inhibiter (e.g. ram-
iprilat) and the inhibitor ACE complex concentration. It is
assumed that the substrate concentration (S) is much
greater than Et or It and, therefore, S is a constant, equal
to the fixed assay concentration. The reported ACE equi-
librium dissociation constant (Ks) for this substrate is 5
mM [17]. This represents the average for the two sites and,
since the individual values for each site are not known, it
has been assumed that each site has a Ks of 5 mM.
The true "in vivo" enzyme activity is proportional to the
fraction of ACE that is not complexed with inhibitor. This
differs from the measured assay activity because the dilu-
tion associated with the assay results in a time dependent
dissociation of inhibitor during the 60 minute assay. The
experimental assay activity (= Assay60) is defined as the
ratio of the amount of substrate that is hydrolyzed in 60
minutes by the plasma sample in the presence of ACE
inhibitor relative to the activity in the same subject when
no inhibitor is present (before inhibitor administered).
This ratio is the weighted average of the individual cata-
lytic activity of the two sites. In the analysis used here it is
assumed that the two sites are independent and what is
plotted in the Results is the relative activity of each site
which is described by:
The concentration of the inhibitor-enzyme complex
(IEX(t)) decreases during the 60 minute incubation as
inhibitor dissociates because of dilution and competition
with substrate. The value of IEX(t)) is determined from a
solution of a differential equation obtained from eq. (12).
(See the additional file 1
ACE_supplemental_31oct05.doc, section II for details).
Experimental data
The PBPK model was fitted to the results described previ-
ously by van Griensven et. al. [38] of a 3 way crossover
trial using 12 healthy young (19 to 28 years), non-obese
(average weight = 76.25 kg and height = 1.86, BMI 19.9 to
24) males [38]. Only 11 subjects were used in the analysis
because there was no oral data for subject 2. The three
arms of the study were: 1) 2.5 mg oral ramipril; 2) approx-
imately 2.5 mg (range 2.59 – 2.97) IV ramipril given as a
constant 1 min infusion; and 3) approximately 2.5 mg
(range 2.59 – 3.19) IV ramiprilat given as a 1 min infu-
sion.
The value of the antecubital vein plasma ramipril and
ramiprilat and the serum ACE activity (Ventrix kit) was
determined at 0, 5, 10, 20, 30, 45, 60, 90 minutes and 2,
3, 4, 5, 6, 8, 10, 12, 24, and 72 hours. It is assumed that
the antecubital vein concentration can be approximated
by the central vein concentration. The urine concentration
of ramipril, ramiprilat and the major metabolites was
determined at varying times out to 72 hours. The plasma
ramiprilat was determined by a 125I-radioimmunoassay
using rabbit antibodies to ramiprilat. The plasma ramipril
was determined by measuring the difference between the
ramiprilat concentration before and after enzymatic
hydrolysis of the ramipril to ramiprilat. This procedure
could lead to relatively large errors in the ramipril meas-
urements in the presence of high ramiprilat concentra-
tions and is, presumably, the explanation for the large
fluctuations in the plasma ramipril concentrations at long
times (see below). The reported detection limits were 1
ng/ml (2.4 nM) for ramipril and 0.5 ng/ml (1.3 nM) for
ramiprilat [64].
The selection of the parameters was based entirely on sim-
ple trial and error and subjective adjusting of parameters.
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Semi-log plot of model plasma ramiprilat (nanomoles/liter)  following IV ramiprilat in subject 4 (black line) and the corre- sponding fraction of the C and N site of plasma ACE that is  occupied by ramiprilat (red lines) Figure 3
Semi-log plot of model plasma ramiprilat (nanomoles/liter) 
following IV ramiprilat in subject 4 (black line) and the corre-
sponding fraction of the C and N site of plasma ACE that is 
occupied by ramiprilat (red lines). The open squares are the 
experimental plasma ramiprilat values.
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Plasma ramiprilat concentration following IV ramiprilat for subjects 1 to 7 Figure 4
Plasma ramiprilat concentration following IV ramiprilat for subjects 1 to 7.
  ı ?
Subject 1 
Subject 3 
Subject 4  Subject 5 
Subject 6  Subject 7 
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The current version of PKQuest does not allow automated
fitting when more then one data set is used. (In this appli-
cation, parameters must be optimized to fit 4 different
data sets: IV ramiprilat, IV ramipril, oral ramipril and
urine ramiprilat.) In addition, the fitting is complicated
by choices of how to weight the data. Because of the large
fluctuations in plasma ramipril, less weight was given to
the model predictions at low ramipril concentration. The
individual model predictions for each subject and each
data set is shown in the Results section. This is the best
qualitative measure of the model. In addition, the "aver-
age weighted residual error" is tabulated for each individ-
ual data set (Tables 2, 3, 4):
Given the number of adjustable parameters and the com-
plexity of the experimental data, this subjective aspect of
the model fitting cannot be avoided. Several subjects had
a bimodal ramiprilat concentration curve following IV
ramipril with a sharp peak at 5 or 10 minutes that is not
predicted by the model and may be a result of hydrolysis
occurring in the hand and arm tissues drained by the
antecubital vein. These points were not included in the
calculated weighted error. As demonstrated by the param-
eter variation studies described in the Results, some
parameters are highly constrained, while others have wide
ranges of possible values. The major emphasis of this
analysis is on the potential of the PBPK approach to deter-
mine the time and dosage dependence of the ACE inhibi-
tion, not on the quantitative value of the parameters.
Results
IV ramiprilat infusion
Of the 3 sets of data that were modeled, the IV ramiprilat
is the simplest because the ramiprilat systemic input is
known and there is no ramipril present. The ramiprilat
PBPK parameters are: 1) the 4 ACE binding constants (KN,
KC, k-N, k-C, eq. (2)); 2) the renal intrinsic clearance (Clu,
eq. (9)) and 3) the total ACE concentration in plasma and
each tissue (Eti, 1 = 1..12). (The ACE albumin binding (eq.
(4)) was determined directly from experimental measure-
ments). Only two of these parameters (Clu and Etplasma)
are varied to optimize the fit for each subject. The other
parameters were fixed at their "standard values" (see
Methods). Other PBPK parameters, such as tissue volume
and blood flow, extracellular water, tissue albumin, etc.
are taken from the default "standard human" data set that
was determined previously by application of PKQuest to
other solutes.
The confidence limits of values of these model parameters
were determined by an analysis of the sensitivity of the
model predictions to variations in the parameters. A sum-
mary of this analysis is described here. (See the additional
file 1 ACE_supplemental_31oct05.doc section III for a
detailed sensitivity analysis). The values of the renal clear-
ance (Clu), the plasma ACE and the total tissue ACE are
uniquely determined (to within about ± 30%) by the
experimental data. As Brockmeier [35,36] emphasized,
the renal clearance of ramiprilat provides a direct meas-
urement of the fraction that is free in plasma and the
experimental urine ramiprilat excretion data has a crucial
role in the assignment of a unique set of parameters. The
model results are relatively insensitive to the distribution
of the total ACE among the different tissues. The values of
the ramiprilat binding constants (KN, KC, k-N, k-C) cannot
be uniquely determined by the experimental data and
only qualitative constraints can be placed on them. Values
of k-N and k-C varying from 10% of the standard value, up
to infinity provide similar fits. Only the average value of
KN and KC can be uniquely assigned. For example, an iden-
tical KN = KC = 0.140 nM for both sites (equivalent to the
single binding site assumption of Brockmeier [35,36])
provides as good a fit to the data as the "standard" model
(KN = .276, KC = 0.039 nM).
Figure 3 shows the relationship between the plasma con-
centration (black) and the fraction of the N and C sites
that are occupied by ramiprilat (red) for subject 4. The
plasma ACE for subject 4 is 1.65 nM, so that the total
binding site concentration is 3.3 nM. At early times (< 400
minutes), most of the ramiprilat is free, both sites are
nearly 100% occupied, and the plasma ACE is determined
by the renal clearance (Clu) and is independent of the ACE
concentration and binding kinetics. At long times most of
the ramiprilat is bound and the plasma concentration is
determined primarily by the ACE concentration and bind-
ing kinetics. At 72 hours, the total plasma ACE equals 1.68
nM, the C site is 70% occupied, the N site is 24% occupied
and 95% of the ramiprilat is bound to ACE.
Figures 4 and 5 show the model fits for the IV ramiprilat
input data for each of the 11 subjects. Two parameters
were adjusted for each subject – the renal clearance (Clu)
and the plasma ACE concentration. The values of these
two parameters and the weighted average error (eq. (14))
are listed in Table 2. The ramiprilat binding constants and
the ACE tissue/plasma ratio are identical for all subjects.
The agreement between the PBPK model predictions and
the experimental data is quite good, with an average error
of 18%.
IV and oral ramipril infusion
Figure 6 shows the plasma ramipril and ramiprilat data
following an IV bolus infusion of 2.89 mg ramipril in sub-
ject 4. The lines in fig. 6 are the PBPK model predictions
using the optimized standard parameters in Tables 1 and
2. The ramipril is rapidly removed from the systemic cir-
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Plasma ramiprilat concentration following IV ramiprilat for subjects 8 to 12 Figure 5
Plasma ramiprilat concentration following IV ramiprilat for subjects 8 to 12.
Subject 12
Subject 10 Subject 11
Subject 8 
Subject 9 
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culation while the ramiprilat appearance is significantly
delayed. This delay results from the intracellular accumu-
lation and slow release of the ramiprilat produced from
ramipril in the liver and kidney (fig. 1). There are large
fluctuations in the plasma ramipril curve at long time and
low concentrations that cannot be attributed to enterohe-
patic recirculation since it would require impossibly large
and rapid rates of secretion and reabsorption. It is
assumed that this fluctuation is an artifact of the analytical
ramipril methodology discussed in the Methods. Seven
parameters are required to model the IV ramipril experi-
ments (see Methods): Clint_L, Clint_K and FrL describe the
liver and kidney metabolism of ramipril and its conver-
sion to ramiprilat; PsL and PsK describe the rate that this
ramiprilat leaves the liver and kidney and enters the sys-
temic circulation; PsT  describes the rate that ramipril
enters the intracellular water of the peripheral tissues and
fu_cell describes the intracellular fraction unbound which
determines the ramipril equilibrium volume of distribu-
tion. Figure 7 shows the plasma ramipril and ramiprilat
following an oral dose of 2.5 mg ramipril in the same sub-
ject. Five additional parameters (AD, a, T, AR, Aslow) are
required to model the oral ramipril intestinal absorption.
In total, 12 new parameters are required to describe the
oral and IV ramipril data. Although it is not possible to
specify a unique, quantitative parameter set, an analysis of
the sensitivity of the model fits to variation in the param-
eters indicates that all of these parameters make signifi-
cant contributions to the quality of the model fit. This
sensitivity analysis is summarized here. (See the addi-
tional file 1 ACE_supplemental_31oct05.doc section IV
for a detailed analysis).
The 3 metabolic parameters (Clint_L, Clint_K  FrL) are
required to describe conversion of ramipril to systemic
ramiprilat in the kidney and liver. The requirement for
these two organ components arises from the different way
the liver and kidney act on an IV (no first pass metabo-
lism) versus an oral input (with first pass metabolism). A
significantly poorer fit is obtained if only liver metabo-
lism is included in the model. The parameters PsL and PsK
characterize the rate that the intracellular ramiprilat pro-
duced from ramipril enters the systemic circulation from
the liver and kidney. They are adjusted to fit the delayed
systemic appearance of ramiprilat following IV or oral
ramipril and are determined within factors of about 30%
by the experimental data. The sensitivity analysis indicates
that a finite peripheral tissue cell membrane ramipril per-
meability (PsT), which allows the ramipril to distribute in
all the body water, clearly provides a better fit then
restricting the ramipril to the extracellular space. Any per-
meability value ranging from the standard value up to
infinity provides an equally good fit.
Five parameters are required to describe the intestinal
absorption of oral ramipril. The major component is
described by the 3 parameter (A, a and T) gamma distri-
bution function (eq. (10)) which is routinely used to
describe oral uptake in PKQuest [5]. In some subjects
there is an early peak in the plasma ramiprilat following
oral ramipril that can only be explained by adding an
absorption component (AR) where the ramipril is directly
converted to ramiprilat either in the intestinal lumen or
epithelial cell and directly absorbed, bypassing the slower
liver and kidney pathways. Finally, in some subjects the
plasma ramiprilat following oral ramipril remained con-
stant between 200 and 3000 minutes (about 2 days),
requiring the addition of a slow delayed ramipril absorp-
tion component (Aslow), presumably representing entero-
hepatic recirculation and/or large intestinal absorption.
Figures 8, 9, 10, 11, 12, 13 show the model plots and
Tables 2, 3 and 4 list the values of the adjustable parame-
ters for the IV and oral ramipril input for each of the 11
subjects. The plots provide a good view of the large indi-
vidual variation. For example, although the plasma rami-
pril concentration following an IV ramipril dose is nearly
identical for subjects 1 and 4 (fig. 8), the resulting peak
plasma ramiprilat concentration for subject 4 is nearly 5
times higher than for subject 1 (fig. 8). This is an indica-
tion of the large subject to subject variation in ramipril
metabolism. It can be seen that the PBPK model provides
an adequate description of this variation, with an average
weighted error of about 20% (Tables 2 and 3). The only
exception is subject 5 (fig. 11) where the plasma ramipri-
lat following oral ramipril falls much more rapidly to
non-detectable levels than the model predicts. Figure 14
shows a plot of the sum of the intestinal absorption rate
of the major and slow ramipril components for all sub-
jects. (This does not include the direct ramiprilat absorp-
tion component.) The total oral absorption varies from
1500 to 3487 nanomoles, representing 25 to 58% of the
2.5 mg dose. The average total absorption was 35% of the
oral dose. This is 12% greater than the 23.2% total
amount of ramipril and its metabolites that was recovered
in the urine in these same subject [38] and is consistent
with measurements of Verho et. al. [65] that an additional
17% of the oral dose is excreted in the bile in humans.
ACE assay
In addition to the ramipril and ramiprilat concentrations,
the experimental ACE activity was also determined for
each plasma sample. What is reported is the fractional
enzyme activity which is defined as equal to the amount
of the test substrate hydrolyzed in 60 minutes relative to
the hydrolysis in the absence of ACE inhibitor (see Meth-
ods). This activity is proportional to the fraction of the
ACE sites that are unoccupied by ramiprilat. The assay
activity is not equal to the true in vivo activity because theBMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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ramiprilat dissociates (and enzyme activity increases) dur-
ing the 60 minute assay because of assay dilution and
competition with the test substrate.
Figure 15 shows an example of the change in activity (as a
fraction of the maximum activity when no inhibitor is
present) during the 60 minute ACE assay. The ramiprilat
concentration (before dilution) for this plot is 1.3 nM,
79% of the concentration of each ACE site for subject 4
Plasma ramipril (top panels) and ramiprilat (bottom panels) following IV ramipril for subject 4 Figure 6
Plasma ramipril (top panels) and ramiprilat (bottom panels) following IV ramipril for subject 4. Left column: early time data on 
absolute scale. Right column: long time data on semi-log scale. The open squares are the experimental plasma values. The 
dashed red line indicates ramipril detectable limit and the red square indicates that the plasma value was below this limit.
Subject 4:    IV Ramipril   
?
Plasma Ramipril (nM)
Plasma Ramiprilat (nM) BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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(1.65 nM). It can be seen that for the high affinity C site
(KC = 0.039 nM) there is little change in inhibitor binding,
while for the lower affinity N site (KN = .276 nM), there is
a large change during the 60 minutes as the ramiprilat dis-
sociates because of the assay dilution. The activity at time
= 0, before any ramiprilat dissociation occurs, corre-
Plasma ramipril (top panels) and ramiprilat (bottom panels) following oral ramipril for subject 4 Figure 7
Plasma ramipril (top panels) and ramiprilat (bottom panels) following oral ramipril for subject 4. Left column: early time data. 
Right column: all data. The open squares are the experimental plasma values. The dashed red line indicates the analytical detec-
tion limit for ramipril.
Subject 4:    Oral Ramipril  
Plasma Ramipril (nM)
Plasma Ramiprilat (nM) BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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sponds to the "true", in vivo plasma activity. The meas-
ured activity is the average activity during the 60 minutes
incubation (Assay60, eq. (13)). Figure 16 shows a compar-
ison of the "true" in vivo fractional ACE inhibition (at t =
0) versus the 60 minute assay activity for varying concen-
trations of the plasma ramiprilat. For the high affinity C
site, the experimental assay does not differ significantly
from the true activity, while for the lower affinity N site
the assay activity can be as much as 70% greater than the
true activity.
The plasma ACE activity as a function of time was deter-
mined experimentally for all 3 arms of the study using the
60 minute Vertex assay. Figure 17 shows a comparison of
the PBPK model predictions of the "true" in vivo fraction
of the C and N sites that are inhibited versus the experi-
mentally measured ACE fraction inhibited (squares) for
the IV ramiprilat, IV ramipril and oral ramipril input in
subject 4. If the two sites are independent, the experimen-
tal ACE activity should be the weighted average of the
individual catalytic activity of the N and C sites which
have different substrate selectivity [19,21,66]. Since there
is no information about the individual site activity for the
substrate used in this assay ([3H]benzoylglycylglycylgly-
cine), one cannot determine which one (or both) of the
sites is being assayed by this procedure. The ACE activity
is closest to that of the N site suggesting that this substrate
is hydrolyzed primarily by the N site. (For the N site, the
assay activity should be about 50% greater than the "true"
fraction inhibited, see fig. 16). The relationship between
the fraction of the sites occupied by ramiprilat and the
experimental activity will be further complicated if there is
negative cooperativity between the sites, as suggested by
Skirgello et. al. [20]
Discussion
Validity of the PBPK model
Although the PBPK model (fig. 1) is complicated, as dis-
cussed above (Results) it represents the minimum
PBPK model (solid line) plasma ramipril (left column) and  ramiprilat (right column) following IV ramipril for subjects 1  to 5 Figure 8
PBPK model (solid line) plasma ramipril (left column) and 
ramiprilat (right column) following IV ramipril for subjects 1 
to 5. The open squares are the experimental data.
PBPK model (solid line) plasma ramipril (left column) and  ramiprilat (right column) following IV ramipril for subjects 6  to 9 Figure 9
PBPK model (solid line) plasma ramipril (left column) and 
ramiprilat (right column) following IV ramipril for subjects 6 
to 9. The open squares are the experimental data.BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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arrangement required to describe the experimental rami-
pril/ramiprilat kinetics. There is direct experimental evi-
dence that qualitatively supports all of the model
assumptions. The following lists the major assumptions
of the model along with the experimental support.
1. Plasma ACE has two independent high affinity binding
sites (N and C terminal) with kinetics described by eq. (2).
This is directly supported by in vitro measurements
[19,21]. However, the only known values of the kinetic
constants for ramiprilat binding are at 4°C and 300 mM
NaCl (see Methods). For lack of better information, these
are the values that have been used in the PBPK model.
2. Tissue ACE is identical to circulating plasma ACE. The
strongest support for this assumption is that it has been
shown that plasma ACE is directly derived from the mem-
brane bound tissue ACE by post-translational proteolytic
cleavage [28,29]. This is a critical assumption. Tissue ACE
represents more than 90% of the total ACE and is the site
of the clinical action of the ACE inhibitors [9]. This
assumption allows one to use a single set of binding con-
stants derived from in vitro measurements on tissue ACE
to predict the plasma and tissue kinetics.
3. Ramiprilat is an extracellular solute and ramipril dis-
tributes in all the body water. The ramiprilat assumption
is supported by the relatively low ramiprilat octanol/water
distribution coefficient of 0.011 at pH 7.0 [42]. Direct
support for this assumption is provided by the observa-
tion that ramiprilat has a very slow rate of crossing the
blood-brain barrier, with a free ramiprilat CSF/Plasma
ratio of about 0.02 2 hours after an IV ramiprilat injection
in dogs [67]. This assumption simplifies the description of
the ramiprilat distribution kinetics since it allows the use
of the previously determined PBPK set of extracellular vol-
ume and albumin binding parameters [6]. (The special
transport systems that extrude ramiprilat from liver and
kidney cells are an exception to this assumption). In con-
trast, the free ramipril CSF/Plasma ratio 2 hours after IV
ramipril is about 2 [67], supporting the model assump-
tion that ramipril has a high cell membrane permeability
and distributes in all the body water.
4. Both the liver and kidney cells take up ramipril, hydro-
lyze it to ramiprilat and release it back to the circulation.
PBPK model (solid line) plasma ramipril (left column) and  ramiprilat (right column) following IV ramipril for subjects 10  to 12 Figure 10
PBPK model (solid line) plasma ramipril (left column) and 
ramiprilat (right column) following IV ramipril for subjects 10 
to 12. The open squares are the experimental data. PBPK model (solid line) plasma ramipril (left column) and  ramiprilat (right column) following oral ramipril for subjects 1  to 5 Figure 11
PBPK model (solid line) plasma ramipril (left column) and 
ramiprilat (right column) following oral ramipril for subjects 1 
to 5. The open squares are the experimental data.BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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The PBPK modeling of the rate of uptake, metabolism and
release determines the kinetics of plasma ramipril and
ramiprilat following a ramipril input. The investigations
of Pang and colleagues [43-49] of enalapril and enalapri-
lat kinetics in perfused rat liver and kidney provide direct
qualitative confirmation of this assumption. For the sub-
jects in this study, 0 to 60% (mean = 25%) of the total
ramipril metabolism occurs in the kidney (Table 3). This
is consistent with the observation that ramipril clearance
decreases by about 50% in patients with renal failure [68-
70]. (One publication found no change in ramipril clear-
ance in renal failure [71].)
5. The only site of ramiprilat removal is renal clearance.
This is consistent with the observation of a 3 to 4 fold
decrease in ramiprilat clearance in renal failure patients
with a 3 to 4 fold reduction in creatinine clearance
[69,71].
6. All of the ramiprilat produced from ramipril by the kid-
ney is released back to the systemic circulation and is not
excreted in the urine. This can be directly tested by com-
paring the renal ramiprilat clearance for the IV ramipril
input versus the IV ramiprilat input. If some of the rami-
pril is directly converted to ramiprilat and excreted by the
kidney then one would expect a greater apparent ramipri-
lat clearance with the IV ramipril input. Comparing the
average value of this clearance in the 11 subjects for the
first 240 minutes when most of the ramiprilat is
unbound, there was no significant difference in the clear-
ances for the two inputs (0.364 vs 0.365 l/min).
7. There are 3 components of intestinal absorption of oral
ramipril (Table 4): 1) the major ramipril component
described by a gamma function (eq. (10)) that is similar
to what has been used to describe the absorption of many
other drugs [5] (81% of the total absorption); 2) a much
slower ramipril component that extends out to 3000 min-
utes (13%); 3) direct intestinal conversion of ramipril to
ramiprilat which is then absorbed (6%). The slow compo-
nent could represent either enterohepatic recirculation
[65] or slow absorption from the large intestine. Although
there is no evidence in humans to support the existence of
PBPK model (solid line) plasma ramipril (left column) and  ramiprilat (right column) following oral ramipril for subjects 6  to 9 Figure 12
PBPK model (solid line) plasma ramipril (left column) and 
ramiprilat (right column) following oral ramipril for subjects 6 
to 9. The open squares are the experimental data.
PBPK model (solid line) plasma ramipril (left column) and  ramiprilat (right column) following oral ramipril for subjects  10 to 12 Figure 13
PBPK model (solid line) plasma ramipril (left column) and 
ramiprilat (right column) following oral ramipril for subjects 
10 to 12. The open squares are the experimental data.BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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the direct ramiprilat absorption, Pang et. al. [48] have
observed this component using a perfused rat intestine
preparation.
There are a total of 12 adjustable parameters in the PBPK
model: 4 for ramiprilat (renal clearance, plasma ACE, and
renal and liver cell membrane permeability, Table 2); 3
describing the ramipril metabolism and conversion to
ramiprilat (Table 3); and 5 characterizing the rate of oral
ramipril absorption (Table 4). Although this may seem
like a lot, it should be emphasized that they are used to
describe 3 separate data sets (IV ramiprilat, IV ramipril
and oral ramipril) along with the renal ramiprilat excre-
tion data. In addition to describing the distribution and
clearance of ramipril and ramiprilat, this PBPK model also
describes: 1) the liver and kidney cellular uptake and
metabolism of ramipril; 2) the fraction of the total rami-
pril metabolism that is converted to ramiprilat; 3) the rate
of intracellular ramiprilat production in the liver and kid-
ney; 4) the rate that intracellular ramiprilat enters the sys-
temic circulation; 5) the intestinal absorption of ramipril;
and 6) the time dependent binding to plasma and tissue
ACE. For comparison, a simple linear compartmental
model would require a minimum of 15 parameters: 2-
compartment model description of the pharmacokinetics
of the individual ramipril (4 parameters) and ramiprilat
(4 parameters); conversion of ramipril to ramiprilat (2
parameters) and intestinal absorption (5 parameters).
Additional parameters would be required to describe the
non-linearity and the individual C and N binding sites.
The PBPK model uses experimentally realistic parameters
and, as shown in figs. 4 and 5 and figs. 8, 9, 10, 11, 12, 13,
provides a good description of the individual subject var-
iation, with an average weighted residual error of about
20% for all the data (Table 2 and 3).
Clinical implications
There is now a general consensus that the most rational
approach to answering questions about dosage and effi-
cacy of the different ACE inhibitors should be based on an
analysis of the quantitative inhibition of tissue ACE [9].
The most direct approach to this question is to measure
the plasma ACE activity as a function of time. This should
provide a good measure of tissue ACE inhibition because,
as is shown below, tissue and plasma ACE should have the
same fractional inhibition at long times. Unfortunately,
the standard plasma ACE activity measurements have an
uncertain relationship to the true in vivo activity for two
reasons: 1) During the assay, the ACE activity decreases
because of dilution of the ACE inhibitor (see figs. 15 and
16); and 2) the assay represents a weighted average of the
sum of the activity of the N and C sites for the test sub-
strate used in the assay (see fig. 17). The activity of the C
site is most important for the renin-angiotensin system,
Variation of the ACE activity (= fraction of N and C ACE  sites not occupied by ramiprilat) during the 60 minute incu- bation with the test substrate during the standard ACE assay Figure 15
Variation of the ACE activity (= fraction of N and C ACE 
sites not occupied by ramiprilat) during the 60 minute incu-
bation with the test substrate during the standard ACE assay. 
The activity at time 0 represents the true in vivo fractional 
ACE activity.
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PBPK model (solid line) rate of intestinal ramipril absorption  (sum of fast and slow components) for all subjects Figure 14
PBPK model (solid line) rate of intestinal ramipril absorption 
(sum of fast and slow components) for all subjects.
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since, at physiological conditions (37°C, 50 mM NaCl)
the C site has a 3 fold higher kcat and a 2.7 fold higher kcat/
Km for hydrolysis of angiotensin I than the N site [66]. The
C site also has a higher activity for bradykinin and sub-
stance P hydrolysis [72]. Since the physiological inhibitor
and substrate binding constants and the specific assay
substrate activity of the two sites are not known, it is not
possible to relate the assay activity to the true in vivo activ-
ity. Another approach that has been used in animals is
direct measurements of tissue ACE activity using radioin-
hibitor binding [26,59]. However, these displacement
binding measurements suffer from the same problems of
dilution and competition as the plasma assay measure-
ments.
The major advantage of a PBPK model is that it has the
potential to predict the detailed time dependent tissue
ACE activity for arbitrary dosage regimens of the different
ACE inhibitors. The accuracy of these predictions
depends, of course, on the accuracy of the PBPK model.
The major uncertainty in the model described here is the
uncertainty in the value of the ramiprilat binding con-
stants at physiological conditions. Although the values
assumed for the "standard model" which are based on
measurements at 4°C and 300 mM NaCl provide good
fits to the data, other combinations of binding constants
for the two sites also provide good fits. For example, an
equally good fit is obtained by assuming that the two sites
are identical and have a K of 0.14 nM, intermediate
between the standard value for the C site (KC = 0.039 nM)
and the N site (KN = .276 nM). The following analysis uses
the standard model fixed parameters and the average val-
ues of the adjustable parameters (Table 2, 3, 4) to illus-
PBPK model prediction of the true in vivo fraction of C (red)  and N (black) site of plasma ACE that is inhibited by ramipri- lat (black) following IV ramiprilat (top), IV ramipril (middle)  and oral ramipril (bottom) for subject 4 Figure 17
PBPK model prediction of the true in vivo fraction of C (red) 
and N (black) site of plasma ACE that is inhibited by ramipri-
lat (black) following IV ramiprilat (top), IV ramipril (middle) 
and oral ramipril (bottom) for subject 4. The open squares 
are the experimental plasma ACE activity determined by the 
standard assay for subject 4.
Subject 4 
N site  C site 
IV Ramiprilat Input 
IV Ramipril Input 
Oral Ramipril Input 
Comparison of true in vivo fraction of C and N site of ACE  that is inhibited by ramiprilat (black) versus the activity deter- mined from the standard ACE assay (red) as a function of the  plasma ramiprilat concentration Figure 16
Comparison of true in vivo fraction of C and N site of ACE 
that is inhibited by ramiprilat (black) versus the activity deter-
mined from the standard ACE assay (red) as a function of the 
plasma ramiprilat concentration.
N Site 
True 
60 minute assay 
C Site 
True 
60 minute assay 
Concentration dependence of ACE Activity  
              True (in vivo) and AssayBMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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trate the potential of this PBPK analysis. It is assumed that
there is no slow oral absorption component (5 of the 11
subjects had no slow component, Table 4).
The top panel in fig. 18 shows the PBPK plasma ramiprilat
concentration for a 4 day period following a single 2.5 mg
oral dose of ramipril. Also plotted are the ramiprilat con-
Top: model plasma (black), heart (red) and skeletal muscle (green) ramiprilat concentration following oral ramipril in a subject  with average PBPK parameters Figure 18
Top: model plasma (black), heart (red) and skeletal muscle (green) ramiprilat concentration following oral ramipril in a subject 
with average PBPK parameters. Bottom: fraction of C site (left) and N site (right) ACE in plasma (black), heart (red) and skele-
tal muscle (green) that is inhibited by ramiprilat following oral ramipril in same average subject.
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Top: model plasma ramiprilat for entire experimental period (left) and at long times (right) following 2.5 mg (red), 5 mg(black),  10 mg (green) or 20 mg (blue) oral ramiprilat in "average" subject Figure 19
Top: model plasma ramiprilat for entire experimental period (left) and at long times (right) following 2.5 mg (red), 5 mg(black), 
10 mg (green) or 20 mg (blue) oral ramiprilat in "average" subject. Bottom: Fraction of C site (left) or N site (right) inhibited in 
same subject for same set of oral ramipril doses.
5 mg 
2.5 mg
20 mg 
10 mg 
    Average Subject    Oral Ramipril 
N Site 
C Site BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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Top: five day plasma ramiprilat for either once per day 2.5 mg oral ramipril (black) or twice per day 1.25 mg oral ramipril (red) Figure 20
Top: five day plasma ramiprilat for either once per day 2.5 mg oral ramipril (black) or twice per day 1.25 mg oral ramipril (red). 
Bottom: Fraction of C site (left) or N site (right) inhibited in same subject for same multiple dose regimen.
N Site 
C Site 
2.5 mg  once/day 
1.25 mg  twice/day BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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centration in a high (heart) and low (skeletal muscle)
blood flow tissue. After about 600 minutes, most of the
ramiprilat is bound to ACE and the concentration in the
different tissues primarily reflects the difference in the tis-
sue ACE concentration (ACE tissue/plasma = 1.0 for mus-
cle and 1.7 for heart, Table 1). The bottom two panels in
fig. 18 show the fraction of N and C ACE sites that are
occupied by ramiprilat (i.e. the fraction inhibited) in the
plasma and the two tissues. The ACE in the high blood
flow heart rapidly equilibrates with the plasma, while the
low flow skeletal muscle lags slightly behind the plasma.
The differences in fraction inhibited in the different tis-
sues are small and, as a first approximation, the ACE frac-
tional activity in plasma is an accurate measure of the
fractional activity in tissue.
For this 2.5 mg oral dose, which is the lowest that is clin-
ically recommended, the higher affinity C site is 80%
inhibited after 1 day and 55% inhibited after 4 days. Since
the C site has the primary action on the renin-angiotensin
system (see above), a single, daily 2.5 mg dose of ramipril
should reduce the average activity of this system by about
80% or more (assuming the "standard" binding constants
and independent sites).
Figure 19 shows the plasma ramiprilat and the fractional
inhibition of the C and N site as the oral ramipril dose var-
ies from 2.5 to 20 mg, the clinically recommended range.
This figure dramatically illustrates the non-linearity in the
pharmacokinetics produced by the high ACE affinity
binding. At short times, the plasma ramiprilat is roughly
proportional to the dose and most of it is unbound and is
rapidly cleared by the kidney. At long times, most of the
ramiprilat is bound to ACE and the plasma concentration
is determined primarily by the plasma ACE concentration
and is relatively independent of the dose. The fractional
ACE inhibition is also non-linear. This analysis suggests
that increasing the oral dose above 5 mg/day should not
significantly increase the clinical action of the drug since
it does not produce a significant increase in the fraction of
ACE that is inhibited.
Figure 20 shows the plasma ramiprilat and the fractional
inhibition of the C and N site for multiple oral ramipril
doses of either 2.5 mg once per day or 1.25 mg twice a day.
The once/day results agree with the experimental observa-
tion that the plasma concentration reaches a steady state
within one week with increases in peak concentration of
about 1.5 times that of the first dose [73]. An interesting
prediction of this analysis that may be clinically relevant
is that for the lower affinity N site the twice/day regimen
results in a significant increase in the average inhibition.
Figure 21 shows the effect of a reduction in renal function
on the plasma ramiprilat for an oral ramipril dose of 2.5
mg once per day for 4 days. Renal function has two effects
on the pharmacokinetics. About 23% of the conversion of
ramiprilat to ramipril occurs in the kidney (Table 3).
Reducing renal function will produce a small reduction in
plasma ramipril since it will shift some of the metabolism
of ramiprilat from the kidney where 100% is converted to
ramipril, to the liver where only about 25% (FrL, Table 3)
is converted to ramipril. The second effect of a reduction
in a renal function is a proportional reduction in systemic
clearance of ramiprilat. The summation of the two effects
can be seen in fig. 21 – with 50% and 75% reductions in
renal function producing an increase of 1.46 and 2.04 in
the peak ramiprilat concentration on the 4th day (approx-
imately steady state). This increase for a 75% reduction is
similar to the increase on day 12 observed by Schunkert
et. al. [68] in patients with similar reductions in creatinine
clearance.
Although it has been known for many years that ACE con-
tains two functionally distinct and catalytically active
sites, little attention has been paid to the clinical implica-
tions of this. As this PBPK analysis demonstrates, the
quantitative clinical time and dosage dependence of the
ACE inhibition for a particular ACE inhibitor can be pre-
dicted if the in vitro binding kinetics of the two sites for
Influence of reductions in renal function on plasma ramiprilat  following 4 days of 2.5 mg oral ramipril once per day in the  "average" subject Figure 21
Influence of reductions in renal function on plasma ramiprilat 
following 4 days of 2.5 mg oral ramipril once per day in the 
"average" subject.
    Oral Ramipril 
Renal function:  Normal 
50% reduced
75% reduced BMC Clinical Pharmacology 2006, 6:1 http://www.biomedcentral.com/1472-6904/6/1
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that ACE inhibitor are known. Surprisingly, no kinetic
binding measurements at physiological conditions (37°C
and 100 mM NaCl) are available for any ACE inhibitor.
Probably the single most important implication of this
PBPK analysis is to emphasize the importance of the
measurement of these in vitro binding constants.
Conclusion
Because of the high affinity tight binding of the ACE
inhibitors and the presence of two (N and C) ACE binding
sites with different substrate specificity, the standard ACE
assay cannot be directly related to the in vivo inhibition of
the renin-angiotensin system. The error in the assay
depends critically on a number of factors that are currently
not known, such as the inhibitor and substrate binding
constants, the catalytic activity of the two ACE sites for the
assay substrate and possible interaction between sites.
Thus, there are no reliable measurements of the time
dependence of the physiological plasma ACE activity for
any ACE inhibitor. This PBPK model provides the first
quantitative predictions of the pharmacokinetics of the
plasma and tissue ACE inhibition of the individual N and
C binding sites. Its main limitation is that it is assumed
that the N and C site in vitro binding constants deter-
mined at 4°C and 300 mM NaCl are valid at physiological
conditions.
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